Global pharmaceutical company Mylan, Inc. (MYL) Tuesday said the Court of Appeals for the Federal Circuit has ruled in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist.
Commenting on the development, Mylan CEO Heather Bresch said, "We are pleased with the Court's decision as it confirms our original belief in the strength and validity of the intellectual property protecting Perforomist, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease, currently in development. We believe this decision by the Court only further supports the strength of our Specialty franchise."
For comments and feedback: editorial@rttnews.com